Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.

Crombie AL, Antrilli TM, Campbell BA, Crandall DL, Failli AA, He Y, Kern JC, Moore WJ, Nogle LM, Trybulski EJ.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3742-5. doi: 10.1016/j.bmcl.2010.04.068. Epub 2010 Apr 21.

PMID:
20471258
2.

Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis.

Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, Gardell SJ, Crandall DL.

J Thromb Haemost. 2008 Sep;6(9):1558-64. doi: 10.1111/j.1538-7836.2008.03063.x. Epub 2008 Jul 4.

3.

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.

Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL.

J Pharmacol Exp Ther. 2008 Feb;324(2):497-506. Epub 2007 Nov 16.

PMID:
18024786
4.

Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action.

Gardell SJ, Krueger JA, Antrilli TA, Elokdah H, Mayer S, Orcutt SJ, Crandall DL, Vlasuk GP.

Mol Pharmacol. 2007 Oct;72(4):897-906. Epub 2007 Jul 10.

PMID:
17622579
5.

Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1.

Hu B, Jetter JW, Wrobel JE, Antrilli TM, Bauer JS, Di L, Polakowski S, Jain U, Crandall DL.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3514-8.

PMID:
15982877
6.

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.

Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.

J Pharmacol Exp Ther. 2005 Aug;314(2):710-6. Epub 2005 Apr 28.

PMID:
15860572
7.

Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1.

Gopalsamy A, Kincaid SL, Ellingboe JW, Groeling TM, Antrilli TM, Krishnamurthy G, Aulabaugh A, Friedrichs GS, Crandall DL.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3477-80.

PMID:
15177456
8.

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation.

Crandall DL, Hennan JK, Elokdah H, Krishnamurthy G, Antrilli TM, Bauer JS, Morgan GA, Swillo RE.

Biochem Biophys Res Commun. 2003 Nov 28;311(4):904-8.

PMID:
14623266
9.

Release of PAI-1 by human preadipocytes and adipocytes independent of insulin and IGF-1.

Crandall DL, Groeling TM, Busler DE, Antrilli TM.

Biochem Biophys Res Commun. 2000 Dec 29;279(3):984-8.

PMID:
11162462

Supplemental Content

Loading ...
Support Center